Clinical Trials

MAA-304

We are currently enrolling the Hemophilia Phase 3 trial, Crimson-1 (MAA-304)

If you’re interested in participating in this study, please click below for additional information:

For individuals

For physicians

The purpose of the Crimson-1 study is to evaluate the effectiveness and safety of a study medication to treat bleeding episodes in patients 12 and older with congenital Hemophilia A (HA) or Hemophilia B (HB) with inhibitors.

The study drug, known as “MarzAA” is being developed to treat and control bleeding events experienced by individuals with HA or HB with inhibitors. It is administered using a needle placed just under the skin and can be taken at home.

For more information on the Crimson-1 study, including the study locations, please see the information posted on the ClinicalTrials.gov webpage.

To review the MarzAA-related scientific publications, presentations, and posters, click here.

Crimson-1 is an open-label, global, multi-center, randomized, cross-over study designed to evaluate the safety and efficacy of MarzAA for episodic treatment of spontaneous or traumatic bleeding episodes in patients 12 and older with congenital HA or HB with inhibitors, compared with their Standard of Care: either intravenous rFVIIa (NovoSeven or SevenFact) or intravenous activated prothrombin complex concentrates (APCC e.g., FEIBA).

For individuals living with Hemophilia

If you have bleeding episodes caused by Hemophilia, you may want to discuss the potential new therapy being studied in the Crimson-1 clinical trial with your physician.

For more information, please contact Catalyst Biosciences at 304-General@catbio.com.

For physicians

If you are a physician and have a patient who has bleeding episodes caused by Hemophilia with confirmed inhibitors to FVIII or FIX, you may want to learn more about the Crimson-1 study.

For more information, please contact Catalyst Biosciences at 304-General@catbio.com.

X